期刊文献+

两种化学治疗方案治疗术后乳腺癌的临床比较 被引量:2

下载PDF
导出
摘要 目的对比观察临床应用TA方案与CAF方案治疗术后乳腺癌的疗效及经济性。方法选取2006年5月至2012年5月确诊为乳腺癌在我院行术后化学治疗的病历75例,其中使用TA方案治疗的35例(n=35),使用CAF方案治疗的40例(n=40),评价两组疗效、毒性反应并进行药物经济学比较。结果 TA组总有效率为82.87%,CAF组总有效率为65.00%,两组比较差异有显著性(P<0.05);两组患者主要不良反应为恶心呕吐、脱发、贫血、中性粒细胞减少、心脏毒性和肝功能异常,程度较轻,均能耐受。两组患者各种不良反应的发生率未见显著性差异,均为(P>0.05);CAF组每增加1个效果单位仅需药品成本39.77元,明显优于TA组的127.65元。结论 TA方案的疗效优于CAF方案,但CAF方案有利于减轻患者负担,可作为低收入乳腺癌患者的首选辅助化学治疗方案。
出处 《中国实用医药》 2013年第8期128-129,共2页 China Practical Medicine
  • 相关文献

参考文献3

二级参考文献16

  • 1Garces CA, Cance WG. Neoadjuvant chemotherapy of breast cancer. Am Surg, 2004,70 : 565-569.
  • 2Charfare H, Limongelli S, Purushotham AD, et al. Neoadjuvant chemotherapy in breast cancer. Br J Surg,2005, 92:14-23.
  • 3Abrial SC, Penault-Llorca F, Delva R, et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat,2005, 94: 255-263.
  • 4Penault-Llorea F, Cayre A, Bouchet-Mishellany F, et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol,2003, 22: 1319-1325.
  • 5Petit T, Wilt M, Velten M, et al. Comparative value of tumor grade hormonal receptors, Ki 67, HER 2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer, 2004,40 : 205 -211.
  • 6Gregory RK, Powles TJ, Salter J, et al. Prognostic relevance of CerhB2 expression following neoadjuvant chemotherapy in patients in a randomized trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast Cancer Res Treat, 2000,59 : 171 - 175.
  • 7Estevez LG, Guevas JM, Anton A, et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II , muhicenter study. Clin Cancer Res,2003 ,9 :686-692.
  • 8Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol,2008 26 : 1275-1281.
  • 9Carey LA, Dees EC ,Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res ,2007,13:2329-2334.
  • 10Honkoop AH, Luykx-de Bakker SA, Hoekman K, et al. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. Oncologist, 1999,4 : 106-111.

共引文献25

同被引文献20

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部